Genmab A/S (GMAB) vs Insmed (INSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genmab A/S (GMAB) has outperformed Insmed (INSM) over the past year, gaining 10.1% versus a loss of 37.9%. Over five years, INSM leads with a +279.3% price change compared with -18.9% for GMAB. Genmab A/S is the larger company by market cap ($22.82 billion vs $22.04 billion), about 1.0 times the size, while Insmed is growing revenue faster (+66.7% vs +19.2%).
On valuation, Genmab A/S trades at a lower forward P/E (24.3x vs 128.2x for Insmed). Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | INSM |
|---|---|---|
| Share price | $37.12 | $100.93 |
| Market cap | $22.82B | $22.04B |
| 1-day change | +2.95% | +0.45% |
| YTD return | +17.05% | -42.27% |
| 1-year return | +10.11% | -37.90% |
| 5-year return | -18.86% | +279.31% |
| P/E ratio (TTM) | 29.22 | — |
| Forward P/E | 24.34 | 128.18 |
| EPS (TTM) | $1.27 | $-4.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $606.42M |
| Revenue growth (YoY) | +19.19% | +66.73% |
| Net income (latest FY) | $963.00M | $-1.28B |
| Gross margin | 93.60% | 79.73% |
| Operating margin | 28.63% | -205.59% |
| Net margin | 25.89% | -210.54% |
| 52-week high | $40.17 | $212.75 |
| 52-week low | $23.62 | $90.39 |
| Distance from 52-week high | -7.61% | -52.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +16.45% | +95.92% |
| Average volume | 2.83M | 2.60M |
| Shares outstanding | 614.90M | 218.38M |
| Employees | 3,119 | 1,664 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMAB has outperformed INSM by 48.0 percentage points over the past year.
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs +19.19%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
GMAB vs INSM FAQ
Which is bigger, Genmab A/S or Insmed?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.82B compared with $22.04B for Insmed (INSM).
Which stock has performed better over the past year, GMAB or INSM?
GMAB returned +10.11% over the past 12 months, compared with -37.90% for INSM (price return, excluding dividends). Past performance does not predict future results.
Are Genmab A/S and Insmed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.